Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity

  • Regeneron Pharmaceuticals Inc REGN earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. 
  • Sales decreased 44% to $2.85 billion, surpassing the analysts' consensus of $2.79 billion.
  • Total revenues excluding REGEN-COV and Ronapreve revenues increased by 20%. No REGEN-COV sales were recorded as the company had completed its final deliveries under its agreements with the U.S. government.
  • Q2 U.S. Eylea sales increased 14% Y/Y to $1.62 billion. 
  • The company obtained the exclusive right to Libtayo from Sanofi SA SNY for a $900 million up-front payment. Sanofi is eligible to receive a $100 million regulatory milestone and $100 million in sales-based milestones.
  • Concurrently, Regeneron announced initial data from an ongoing Phase 1/2 trial of REGN5678 in combination with Libtayo (cemiplimab) in advanced metastatic castration-resistant prostate cancer. 
  • Preliminary data showed dose-dependent anti-tumor activity. 
  • At the lowest dose levels (cohorts 1-5), there was almost no evidence of anti-tumor activity, with only 1 of 17 patients showing a decrease (22%) in prostate-specific antigen.
  • At the higher dose levels (cohorts 6-8), evidence of dose-dependent anti-tumor activity was generally seen within six weeks of starting combination treatment.
  • Price Action: REGN shares are up 8.16% at $621.88 during the market session on the last check Wednesday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!